Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 6 Dec 2021

Griesel Rulan, Maartens Gary, Chirehwa Maxwell, Sokhela Simiso, Akpomiemie Godspower, Moorhouse Michelle, Venter Francois, Sinxadi Phumla

Abstract excerpt

BACKGROUND: Dolutegravir is associated with more weight gain than efavirenz. Loss-of-function polymorphisms in CYP2B6 result in higher efavirenz concentrations, which we hypothesized would impair weight gain among people living with human immunodeficiency virus (HIV; PLWH) starting efavirenz-based antiretroviral therapy (ART). METHODS: We studied ART-naive participants from the ADVANCE study randomized to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Benzoxazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Cytochrome P-450 CYP2B6

Share to Heterocyclic Compounds, 3-Ring

Share to Oxazines

Share to Pyridones

Share to Weight Gain

Source

Open in PubMed Open full text

Identifiers

PMID: 32960272
DOI: 10.1093/cid/ciaa1073
PMCID: PMC8653639

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.PMID 32960272Read ↗

Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?Semantic proximity Read ↗

Obesity-Related Single-Nucleotide Polymorphisms and Weight Gain Following First-Line Antiretroviral Therapy.Semantic proximity Read ↗

Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.Semantic proximity Read ↗

Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy.Semantic proximity Read ↗

Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial.Semantic proximity Read ↗

Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana.Semantic proximity Read ↗

Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weightSemantic proximity Read ↗

Weight Loss Associated with Semaglutide Treatment Among People with HIVSemantic proximity Read ↗

Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.Semantic proximity Read ↗

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.